Oklahoma City Doctor Surrenders Dispensing Authority and Pays $130,000 to Settle Civil Penalty Claims Stemming from Allegations of Recordkeeping Violations

OKLAHOMA CITY – Richard Swenson, M.D. (“Dr. Swenson”), paid $130,000 to settle civil penalty claims stemming from allegations that he violated the Comprehensive Drug Abuse Prevention and Control Act of 1970 (“Act”) and its regulations, announced United States Attorney Robert J. Troester. Dr. Swenson also agreed to permanently cease dispensing and administering controlled substances as of April 3, 2025.

Recordkeeping is a vital part of managing controlled substances. A registrant who purchases controlled substances must comply with the purchase record requirements contained in the regulations implementing the Act. Maintaining complete and accurate records help avoid diversions and losses of controlled drugs. Failure to do so subjects the registrant to civil monetary penalties.

During the relevant time, Dr. Swenson practiced medicine at Accident Care and Treatment Center, Inc. in Oklahoma City, Oklahoma. The United States alleges that from April 2022, through April 2024, Dr. Swenson failed to maintain DEA Forms 222 for certain purchases of Hydrocodone/Acetaminophen, which is an opioid and a Schedule II controlled substance. During this time period, the United States further alleges that Dr. Swenson also failed to maintain records for certain purchases of Schedule III and Schedule IV controlled substances. To resolve these allegations, Dr. Swenson agreed to pay $130,000 to the United States and to permanently refrain from dispensing and administering controlled substances. Dr. Swenson is still permitted to prescribe controlled substances consistent with his DEA Registration.

In reaching this settlement, Dr. Swenson did not admit liability, and the government did not make any concessions about the legitimacy of the claims. The agreement allows the parties to avoid the delay, expense, inconvenience, and uncertainty involved in litigating the case.

This case was investigated by the Drug Enforcement Administration, Office of Diversion Control. Assistant U.S. Attorneys Amanda R. Johnson and Ronald R. Gallegos prosecuted the case.